SelectQuote, Inc. (SLQT) Stock Analysis and Metrics

SelectQuote

NYSE: SLQT

$0.65 ▼ -0.05 (-6.57%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap132.62 Mn

P/E6.39

P/S0.08

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)375.78 Mn

Revenue Growth (1y) (Qtr)5.58

Add ratio to table…

About

SelectQuote, Inc. is a leading technology-enabled, direct-to-consumer distribution and engagement platform for selling insurance policies and healthcare services. The company operates through three primary business segments: Senior, Life and Auto & Home insurance distribution, and Healthcare Services. SelectQuote leverages over 40 years of data and proprietary artificial intelligence to optimize lead acquisition, agent routing, and customer lifecycle management, with a focus on maximizing the lifetime value of commissions.

SelectQuote generates revenue primarily through commissions earned from insurance carrier partners for policies sold on their behalf. The company does not underwrite insurance policies and bears no underwriting risk, instead acting as a distributor that matches consumers with insurance products from its carrier partners. Revenue is also derived from its Healthcare Services segment, which offers pharmacy products, chronic care management, and health navigation services to consumers, particularly seniors, through its SelectRx, SelectPatient Management, and Healthcare Select platforms.

The company operates through the following segments: Senior, Life and Auto & Home insurance distribution, and Healthcare Services.

• Senior: This segment provides unbiased comparison shopping for Medicare Advantage and Medicare Supplement insurance plans, as well as prescription drug, dental, vision, hearing, and critical illness products. SelectQuote represents approximately 25 leading nationally-recognized insurance carrier partners, including those owned by UnitedHealthcare, Humana, Wellcare, and Aetna. In the year ended June 30, 2025, MA and MS plans accounted for 90% of approved Senior policies, with term life and final expense products making up the remainder.

• Life: This segment offers term life, final expense, critical illness, accidental death, and juvenile insurance products through unbiased comparison shopping. SelectQuote works with approximately 20 leading nationally-recognized insurance carrier partners, many of which have relationships exceeding 20 years. For the year ended June 30, 2025, term life policies accounted for 40% of new premium within the Life division, while final expense policies accounted for 60%.

• Auto & Home: This segment distributes homeowners, auto, dwelling fire, and other ancillary insurance products through unbiased comparison shopping. SelectQuote partners with approximately 20 leading nationally-recognized insurance carriers, including Safeco, Progressive, and Travelers. Homeowners and auto products represented 83% of new premium within the Auto & Home division for the year ended June 30, 2025, with dwelling fire and other products making up the rest.

• Healthcare Services: This segment offers pharmaceutical products and health-related services through SelectRx, Healthcare Select, and SelectPatient Management (SPM). SelectRx is a Patient-Centered Pharmacy Home TM accredited pharmacy providing essential prescription and over-the-counter medications, customized packaging, and medication therapy management. Healthcare Select engages customers through health risk and lifestyle assessments to offer personalized health-related products and services. SPM, launched in 2024 after the acquisition of a chronic care management platform, provides scalable, technology-enhanced services for patients with chronic conditions to help them navigate the care continuum.

SelectQuote holds a strong position in the insurance distribution industry as a pioneer of direct-to-consumer term life insurance exchange and a leader in leveraging technology for personalized consumer engagement. The company differentiates itself through its proprietary technology platform, which integrates AI-driven lead scoring, intelligent routing, and workflow optimization to maximize agent productivity and customer lifetime value. Key competitors include eHealth, Inc. and GoHealth, Inc., but SelectQuote maintains a competitive edge through its scale, data assets accumulated over four decades, and deep relationships with major insurance carriers such as UnitedHealthcare, Humana, Aetna, and Wellcare.

SelectQuote serves individual consumers seeking insurance and healthcare solutions, with a primary focus on seniors aged 65 and older. The company's customer base includes individuals shopping for Medicare Advantage and Supplement plans, life insurance, auto and home insurance, and healthcare services such as pharmacy fulfillment and chronic care management. Specific customer names are not disclosed in the filing, but the company engages directly with consumers through its direct-to-consumer model and partners with insurance carriers and healthcare providers to deliver its services.

Investment Thesis

▲ Bull case

SelectQuote demonstrated a revenue to customer acquisition cost multiple of 6.7 times for the twelve months ended March 2026 marking a high water mark for the business and indicating that each dollar spent on acquiring a policy generates substantially more revenue over the life of the customer relationship. This efficiency reflects strong agent productivity and improved marketing spend effectiveness as shown by a 14% reduction in cost per approved policy compared to two years prior. The high multiple underscores the durability of the company's model where commissions receivable represent a large pool of future cash flow that is not fully reflected in the current equity valuation. Investors may be underestimating the ability to monetize this receivable balance through structured finance or securitization which could unlock significant value.
The Senior division delivered adjusted EBITDA margin of 26% after excluding the favorable receivable adjustment marking the fourth consecutive year of at least 25% margin despite widely varying Medicare Advantage environments. This consistency shows that the company's agent centric model and customer retention capabilities generate reliable profitability even when external factors such as plan bid fluctuations or carrier mix shift. The business also reported a 34% recapture rate over the last two disruptive seasons indicating strong policyholder loyalty and an ability to replace lost business with new policies. These operational strengths suggest that the Senior segment can continue to produce steady cash flow as the Medicare market stabilizes and carriers pursue disciplined pricing for 2027 and beyond.
SelectRx demonstrated impressive operational momentum with a 64% increase in prescriptions shipped versus two years ago while membership grew 55% over the same period indicating that existing users are utilizing the platform more intensely. The Olathe Kansas distribution facility is already achieving more than 30% efficiency gains relative to legacy sites and operates at less than half capacity with a single shift leaving ample room to scale volume without proportional cost increases. Management expects the Healthcare Services segment to reach a 40,000,000 to 50,000,000 EBITDA run rate in the near term as the proprietary pharmacy management system completes testing and enables higher throughput from the Olathe site. These trends point to a hidden catalyst where incremental prescription volume contributes largely to profit given the relatively fixed cost base of the pharmacy network.
Management highlighted ongoing efforts to delever the balance sheet and noted that the company has already completed one securitization transaction and continues to evaluate additional capital markets options including further receivable backed financing or selective M&A. The commissions receivable balance approaching 1,000,000,000 dollars provides a sizable collateral base that could support lower cost funding and reduce interest expense which currently absorbs roughly 10,000,000 dollars per quarter. Successfully executing such transactions would not only strengthen the financial profile but also validate the market's confidence in the longevity of the cash flows underlying the receivable asset. This creates a pathway to narrow the gap between the intrinsic value of the cash flow stream and the current equity price which management views as wildly dislocated.
SelectQuote Local represents a low capital investment franchise model that extends the company's data and technology platform to community based healthcare and life insurance providers allowing them to leverage SelectQuote's market advantages without requiring the firm to build out a physical sales force. While the initiative is not expected to be a meaningful revenue driver in the near term it expands the addressable market and deepens the company's footprint in underserved areas potentially creating network effects that enhance the value of the core insurance and pharmacy businesses over time. The approach mirrors the successful expansion of the revenue to CAC metric seen in Healthcare Services and suggests that management is actively seeking avenues to compound cash flow growth with minimal incremental investment. This strategic flexibility could become a source of future upside that is not yet priced into the stock.

SelectQuote demonstrated a revenue to customer acquisition cost multiple of 6.7 times for the twelve months ended March 2026 marking a high water mark for the business and indicating that each dollar spent on acquiring a policy generates substantially more revenue over the life of the customer relationship. This efficiency reflects strong agent productivity and improved marketing spend effectiveness as shown by a 14% reduction in cost per approved policy compared to two years prior. The high multiple underscores the durability of the company's model where commissions receivable represent a large pool of future cash flow that is not fully reflected in the current equity valuation. Investors may be underestimating the ability to monetize this receivable balance through structured finance or securitization which could unlock significant value.
The Senior division delivered adjusted EBITDA margin of 26% after excluding the favorable receivable adjustment marking the fourth consecutive year of at least 25% margin despite widely varying Medicare Advantage environments. This consistency shows that the company's agent centric model and customer retention capabilities generate reliable profitability even when external factors such as plan bid fluctuations or carrier mix shift. The business also reported a 34% recapture rate over the last two disruptive seasons indicating strong policyholder loyalty and an ability to replace lost business with new policies. These operational strengths suggest that the Senior segment can continue to produce steady cash flow as the Medicare market stabilizes and carriers pursue disciplined pricing for 2027 and beyond.
SelectRx demonstrated impressive operational momentum with a 64% increase in prescriptions shipped versus two years ago while membership grew 55% over the same period indicating that existing users are utilizing the platform more intensely. The Olathe Kansas distribution facility is already achieving more than 30% efficiency gains relative to legacy sites and operates at less than half capacity with a single shift leaving ample room to scale volume without proportional cost increases. Management expects the Healthcare Services segment to reach a 40,000,000 to 50,000,000 EBITDA run rate in the near term as the proprietary pharmacy management system completes testing and enables higher throughput from the Olathe site. These trends point to a hidden catalyst where incremental prescription volume contributes largely to profit given the relatively fixed cost base of the pharmacy network.
Management highlighted ongoing efforts to delever the balance sheet and noted that the company has already completed one securitization transaction and continues to evaluate additional capital markets options including further receivable backed financing or selective M&A. The commissions receivable balance approaching 1,000,000,000 dollars provides a sizable collateral base that could support lower cost funding and reduce interest expense which currently absorbs roughly 10,000,000 dollars per quarter. Successfully executing such transactions would not only strengthen the financial profile but also validate the market's confidence in the longevity of the cash flows underlying the receivable asset. This creates a pathway to narrow the gap between the intrinsic value of the cash flow stream and the current equity price which management views as wildly dislocated.
SelectQuote Local represents a low capital investment franchise model that extends the company's data and technology platform to community based healthcare and life insurance providers allowing them to leverage SelectQuote's market advantages without requiring the firm to build out a physical sales force. While the initiative is not expected to be a meaningful revenue driver in the near term it expands the addressable market and deepens the company's footprint in underserved areas potentially creating network effects that enhance the value of the core insurance and pharmacy businesses over time. The approach mirrors the successful expansion of the revenue to CAC metric seen in Healthcare Services and suggests that management is actively seeking avenues to compound cash flow growth with minimal incremental investment. This strategic flexibility could become a source of future upside that is not yet priced into the stock.

▼ Bear case

SelectQuote's profitability remains highly dependent on a limited number of insurance carrier partners for its Senior business and any alteration in commission rates or termination of those agreements could directly impact revenue and margins. The company acknowledged that reimbursement rates with pharmacy benefit managers have stabilized only after a prior challenge and that future changes in PBM contracts or drug pricing regulations could reintroduce volatility. Moreover the Medicare Advantage environment continues to be described as mixed with medical cost trends still rising in the high single digits and reimbursement levels insufficient to fully cover those costs creating pressure on carrier profitability that may eventually trickle down to commission structures. This structural reliance on external partners introduces a risk that is not fully captured by the current strong historical performance.
Although SelectRx revenue growth remains solid the segment's adjusted EBITDA margin stands at only 3% indicating that the pharmacy business is still far from contributing meaningfully to overall profitability. Management's target of a 40,000,000 to 50,000,000 EBITDA run rate depends on successful scaling of the Olathe Kansas facility and the deployment of a new proprietary pharmacy management system which is currently in testing and has not yet been proven at scale. Any delay or inefficiency in rolling out the system or in shifting volume from the older Indianapolis and Pittsburgh locations could keep margins depressed and consume cash rather than generate it. The segment's sensitivity to Inflation Reduction Act driven price cuts also shows that external policy shifts can quickly affect top line even if the bottom line impact is modest.
The Life insurance line showed modest revenue growth of 4% year over year but adjusted EBITDA margin declined to 13% from 14% in the prior year reflecting some pressure on profitability. Final Expense continues to be a tailwind while Term Life remains in a highly competitive market where consumers are shifting media consumption habits and digital advertising costs are rising which could erode commissions over time. The mixed performance suggests that the Life division may not provide the steady cash flow contribution that management hopes for especially if Final Expense growth slows or if Term Life faces further disruption from direct to consumer platforms. This uncertainty adds to the overall risk profile of the company's earnings stream.
SelectQuote carries a substantial debt load with long term debt of approximately 353,000,000 dollars and quarterly interest expense net of around 10,000,000 dollars which consumes a meaningful portion of operating cash flow. While management has expressed intent to delever the balance sheet the current capital structure still leaves the company vulnerable to higher interest rates or any tightening of credit conditions that could increase financing costs. The large preferred stock outstanding also carries a significant liquidation preference and accruing dividends that reduce net income attributable to common shareholders limiting the amount of cash flow available for equity holders. This financial leverage may constrain the ability to pursue aggressive growth initiatives or to return capital to shareholders despite improvements in underlying operations.
The company's earnings include a significant non cash add back related to the change in fair value of warrant liabilities which amounted to 27,500,000 dollars in the quarter and has historically caused large swings in reported earnings. This volatility can obscure the true underlying operating performance and may lead investors to question the sustainability of earnings adjustments that are not tied to core business activities. Furthermore the reliance on such adjustments to meet adjusted EBITDA targets could indicate that the core operations are generating less cash flow than the headline numbers suggest. If the warrant liability continues to fluctuate with market conditions the quality of earnings may remain a concern for analysts focused on GAAP profitability.

SelectQuote's profitability remains highly dependent on a limited number of insurance carrier partners for its Senior business and any alteration in commission rates or termination of those agreements could directly impact revenue and margins. The company acknowledged that reimbursement rates with pharmacy benefit managers have stabilized only after a prior challenge and that future changes in PBM contracts or drug pricing regulations could reintroduce volatility. Moreover the Medicare Advantage environment continues to be described as mixed with medical cost trends still rising in the high single digits and reimbursement levels insufficient to fully cover those costs creating pressure on carrier profitability that may eventually trickle down to commission structures. This structural reliance on external partners introduces a risk that is not fully captured by the current strong historical performance.
Although SelectRx revenue growth remains solid the segment's adjusted EBITDA margin stands at only 3% indicating that the pharmacy business is still far from contributing meaningfully to overall profitability. Management's target of a 40,000,000 to 50,000,000 EBITDA run rate depends on successful scaling of the Olathe Kansas facility and the deployment of a new proprietary pharmacy management system which is currently in testing and has not yet been proven at scale. Any delay or inefficiency in rolling out the system or in shifting volume from the older Indianapolis and Pittsburgh locations could keep margins depressed and consume cash rather than generate it. The segment's sensitivity to Inflation Reduction Act driven price cuts also shows that external policy shifts can quickly affect top line even if the bottom line impact is modest.
The Life insurance line showed modest revenue growth of 4% year over year but adjusted EBITDA margin declined to 13% from 14% in the prior year reflecting some pressure on profitability. Final Expense continues to be a tailwind while Term Life remains in a highly competitive market where consumers are shifting media consumption habits and digital advertising costs are rising which could erode commissions over time. The mixed performance suggests that the Life division may not provide the steady cash flow contribution that management hopes for especially if Final Expense growth slows or if Term Life faces further disruption from direct to consumer platforms. This uncertainty adds to the overall risk profile of the company's earnings stream.
SelectQuote carries a substantial debt load with long term debt of approximately 353,000,000 dollars and quarterly interest expense net of around 10,000,000 dollars which consumes a meaningful portion of operating cash flow. While management has expressed intent to delever the balance sheet the current capital structure still leaves the company vulnerable to higher interest rates or any tightening of credit conditions that could increase financing costs. The large preferred stock outstanding also carries a significant liquidation preference and accruing dividends that reduce net income attributable to common shareholders limiting the amount of cash flow available for equity holders. This financial leverage may constrain the ability to pursue aggressive growth initiatives or to return capital to shareholders despite improvements in underlying operations.
The company's earnings include a significant non cash add back related to the change in fair value of warrant liabilities which amounted to 27,500,000 dollars in the quarter and has historically caused large swings in reported earnings. This volatility can obscure the true underlying operating performance and may lead investors to question the sustainability of earnings adjustments that are not tied to core business activities. Furthermore the reliance on such adjustments to meet adjusted EBITDA targets could indicate that the core operations are generating less cash flow than the headline numbers suggest. If the warrant liability continues to fluctuate with market conditions the quality of earnings may remain a concern for analysts focused on GAAP profitability.

Peer Comparison

Companies in the Insurance Brokers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MRSH	Marsh & Mclennan Companies, Inc.	84.27 Bn	20.80	3.02	20.56 Bn
2	AON	Aon plc	75.99 Bn	19.03	4.35	14.66 Bn
3	AJG	Arthur J. Gallagher & Co.	62.23 Bn	38.51	4.17	12.72 Bn
4	WTW	Willis Towers Watson Plc	27.24 Bn	16.09	2.74	6.30 Bn
5	BRO	Brown & Brown, Inc.	23.60 Bn	15.12	3.69	7.89 Bn
6	NP	Neptune Insurance Holdings Inc.	4.12 Bn	-170.66	26.55	0.23 Bn
7	ARX	Accelerant Holdings	3.06 Bn	-2.15	30.17	0.12 Bn
8	CRVL	Corvel Corp	3.03 Bn	28.64	3.22	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password